Compugen Ltd. (CGEN)

Market Cap	201.46M
Revenue (ttm)	59.85M
Net Income (ttm)	1.60M
Shares Out	89.54M
EPS (ttm)	0.02
PE Ratio	125.59
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,187,742
Open	2.150
Previous Close	2.120
Day's Range	2.150 - 2.346
52-Week Range	1.350 - 3.030
Beta	2.59
Analysts	Strong Buy
Price Target	4.00 (+77.78%)
Earnings Date	Mar 4, 2025

About CGEN

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Aug 11, 2000
• Employees: 68
• Stock Exchange: NASDAQ
• Ticker Symbol: CGEN
• Website: https://cgen.com

Financial Performance

In 2023, Compugen's revenue was $33.46 million, an increase of 346.12% compared to the previous year's $7.50 million. Losses were -$18.75 million, -44.34% less than in 2022.

Analyst Forecast

According to one analyst, the rating for CGEN stock is "Strong Buy" and the 12-month stock price forecast is $4.0.

Price Target

$4.0

(77.78% upside)

Analyst Consensus: Strong Buy